Management of anemia in low-risk myelodysplastic syndromes treated with erythropoiesis-stimulating agents newer and older agents |
| |
| Authors: | Roberto Castelli Riccardo Schiavon Valentina Rossi Giorgio Lambertenghi Deliliers |
| |
| Affiliation: | 1.Department of Biomedical and Clinical Sciences Luigi Sacco, Luigi Sacco Hospital Milan,University of Milan,Milan,Italy;2.Hematology and Transfusion Medicine, Department of Oncology and Onco-Hematology, L. Sacco University Hospital,University of Milan,Milan,Italy;3.Fondazione Matarelli Milano,Milan,Italy |
| |
| Abstract: | The myelodysplastic syndromes (MDSs) are clonal hematopoietic stem cell disorders. The International Prognostic Score System (IPSS) groups MDS in lower-risk (IPSS low and intermediate-1) and higher-risk disease (IPSS intermediate-2 and high). AML transformation is the main concern in higher-risk MDS, while anemia and transfusion dependency represent the major issues for low-risk MDS patients. Improving erythropoiesis, and eliminating fatigue and symptoms, is the main therapeutic goal for low-risk MDS patients. Around 50% of MDS patients present with anemia with an Hb level
|
| |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ |
|
